Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Nervous system disorders – page 27

  • 1 389 clinical trials
  • 585 recruiting
  • 453 conditions
  • 29 countries

Conditions in this area

453 conditions with trials, the busiest first

Dementia Alzheimer's type87Multiple sclerosis59Parkinson's disease56Ischaemic stroke52Migraine48Myasthenia gravis43Glioblastoma40Amyotrophic lateral sclerosis31Duchenne muscular dystrophy28Neuroblastoma26Relapsing multiple sclerosis21Glioma20Relapsing-remitting multiple sclerosis20Narcolepsy19Cognitive disorder18Epilepsy18Giant cell arteritis18Partial seizures18Chronic inflammatory demyelinating polyradiculoneuropathy17Spinal muscular atrophy17Anaesthesia16Subarachnoid haemorrhage16Autism spectrum disorder15Insomnia15+429

Clinical trials in Nervous system disorders

1 389 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 389 clinical trials

Heart disease congenital+1

Recruiting

Study on Allopurinol Sodium for Brain Injury Prevention in Newborns with Critical Congenital Heart Disease Undergoing Heart Surgery

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years
  • Substances:Allopurinol Sodium
  • Sponsor:Universitair Medisch Centrum Utrecht

Cerebrovascular accident

Recruiting

Study on Stopping or Continuing Clopidogrel, Carbasalate Calcium, and Dipyridamole for Young Patients After Stroke Without a Known Cause

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Stichting Radboud University Medical Center

Epilepsy

Recruiting

Study on Cannabidiol and Dronabinol for Children with Refractory Epilepsy

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years
  • Substances:Cannabidiol
  • Sponsor:Universitair Medisch Centrum Utrecht

Progressive multiple sclerosis

Recruiting

Study on the Effects of Siponimod for Patients with Secondary Progressive Multiple Sclerosis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Siponimod
  • Sponsor:Azienda Ospedaliera Universitaria Integrata Verona

Ischaemic stroke

Recruiting

Study on Darbepoetin Alfa for Reducing Brain Injury in Newborns with Perinatal Arterial Ischemic Stroke

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years
  • Substances:Darbepoetin Alfa
  • Sponsor:Universitair Medisch Centrum Utrecht

Hereditary neuropathic amyloidosis

Recruiting

Long-Term Safety and Efficacy Study of Eplontersen in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

InvestigationalNo placebo
Countries:CyprusCyprus
  • Participants:18–64 years · 65+ years
  • Substances:Eplontersen
  • Sponsor:Ionis Pharmaceuticals Inc.

Progressive multiple sclerosis

Recruiting

Study on Human Fetal Neural Precursor Cells and Tacrolimus for Patients with Progressive Multiple Sclerosis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Tacrolimus
  • Sponsor:Ospedale San Raffaele S.r.l.

Inguinal hernia+6

Recruiting

Study on the Effect of Levobupivacaine in Reducing Chronic Pain After Open Inguinal Hernia Repair in Patients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Hospital Central De La Defensa Gomez Ulla

Facioscapulohumeral muscular dystrophy

Recruiting

Study of ADS-010 for Adults with Facioscapulohumeral Muscular Dystrophy Type 1

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ads-010
  • Sponsor:Sarepta Therapeutics Inc.

Ischaemic stroke

Recruiting

Comparison of General Anesthesia versus High-Flow Nasal Cannula Sedation in Patients with Acute Ischemic Stroke Undergoing Endovascular Treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Fentanyl Citrate
  • Sponsor:Hospital Universitario La Paz

Chronic inflammatory demyelinating polyradiculoneuropathy

Recruiting

Study on Rituximab for Achieving Remission in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Amsterdam UMC Stichting

Neurogenic bladder

Recruiting

Study on E. coli Polysaccharide for Reducing Antibiotic Use in Patients with Neurogenic Bladder and Recurrent Urinary Tract Infections

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:E.coli Polysaccharide
  • Sponsor:Centre Hospitalier Universitaire De Dijon

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Sodium Chloride72 clinical trialsTemozolomide37 clinical trialsOcrelizumab33 clinical trialsRituximab27 clinical trialsCyclophosphamide25 clinical trialsParacetamol24 clinical trialsCarboplatin15 clinical trialsMethylprednisolone15 clinical trialsPrednisolone15 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.